{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-034551","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.224298+00:00","generated_at":"2026-05-18T08:57:41.028579+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Connect licensee Simcere submits NDA for rademikibart in China for atopic dermatitis","bullets":["Simcere submitted NDA to NMPA for rademikibart to treat atopic dermatitis in adults and adolescents.","Connect eligible for up to $110M in remaining development, regulatory, and commercial milestone payments.","Connect also eligible for tiered royalties up to low double-digit percentages on Greater China net sales.","Rademikibart is a next-generation IL-4Rα antibody; AD market in China estimated at 70M patients.","Connect retains all rights outside Greater China under the 2023 license agreement with Simcere."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-034551","json":"https://secwatch.observer/filing/0001628280-25-034551.json","markdown":"https://secwatch.observer/filing/0001628280-25-034551.md","text":"https://secwatch.observer/filing/0001628280-25-034551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000162828025034551/0001628280-25-034551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000162828025034551/cntb-20250709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:57:41.028579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}